Iuvantium

We are on a mission to treat, cure, and protect as many people as possible from disease to make the world stronger, together. Iuvantium is a pioneering biotech startup tackling the imminent threat of antimicrobial resistance (AMR) to our society, which is projected to reduce global life expectancy by two years by 2035 if left unaddressed. AMR disproportionately affects the elderly and other vulnerable populations prone to hospitalizations, undermining standard and critical medical procedures such as surgeries and cancer treatments. iuvantium's breakthrough platform integrates materials science, translational immunology, and machine learning to engineer precision vaccines against bacterial infections caused by resistant pathogens. Unlike antibiotics, which bacteria develop resistance against in less than three years, iuvantium’s vaccines will provide multi-target, recurrence-free protection by inducing robust immune responses, including the elusive Th17 pathway. This disease-agnostic platform is the first of its kind, offering customizable solutions to prevent AMR infections — among the top 5 hospital killers — and beyond. By advancing rationally designed, life-extending vaccines, iuvantium is transforming global healthcare and protecting the most at-risk populations from the looming AMR crisis.